What is the main purpose of this 8-K filing?

The main purpose of this 8-K filing is to announce and furnish Amgen Inc.'s first-quarter 2024 earnings press release, which contains the company's financial results for the period ended March 31, 2024.

What are non-GAAP financial measures and why does Amgen use them?

Non-GAAP financial measures are financial metrics that exclude certain items from the corresponding GAAP (Generally Accepted Accounting Principles) measures. Amgen uses them to provide a more insightful view of its ongoing business operations, allowing for better comparisons across different periods by excluding items like acquisition-related expenses, restructuring costs, and other non-recurring items that may distort the underlying performance.

What types of expenses does Amgen exclude when calculating non-GAAP results?

Amgen typically excludes acquisition-related expenses (e.g., amortization of acquired intangibles), costs related to restructuring and cost savings initiatives, and certain other items like gains/losses on equity investments or specific legal settlements that are considered outside the ordinary course of business.

Is Free Cash Flow (FCF) a GAAP or non-GAAP measure for Amgen?

For Amgen, Free Cash Flow (FCF) is computed by subtracting capital expenditures from operating cash flow, with both components determined in accordance with GAAP. Thus, FCF itself is presented as a GAAP-based liquidity measure, although it is often discussed alongside non-GAAP operational performance metrics.

AMGN 8-K: Earnings & Results

Summary

Amgen Inc. (AMGN) has filed an 8-K report on May 2, 2024, to announce its first-quarter 2024 financial results. The report primarily furnishes the company's earnings press release, which details both GAAP and non-GAAP financial measures. Investors should note that Amgen utilizes non-GAAP measures to provide a clearer view of its ongoing business operations and facilitate period-over-period comparisons. These non-GAAP adjustments exclude items such as acquisition-related expenses, restructuring costs, and certain other income/expense items deemed outside the ordinary course of business. The company also highlights Free Cash Flow (FCF) as a key liquidity metric. Investors are advised to review the full press release for detailed reconciliations between GAAP and non-GAAP figures.

Key Highlights

1Amgen Inc. reported its first-quarter 2024 financial results on May 2, 2024, via an 8-K filing.
2The filing includes the company's earnings press release for the three months ended March 31, 2024.
3Amgen provides both GAAP and non-GAAP financial measures, with detailed reconciliations for non-GAAP figures.
4Key non-GAAP adjustments include acquisition-related expenses, restructuring costs, and certain other unusual items.
5The company emphasizes Free Cash Flow (FCF) as an important measure of liquidity.
6Management uses non-GAAP measures internally for budgeting, financial planning, and performance evaluation.
7The information furnished in this 8-K is not considered 'filed' for certain regulatory purposes.

AMGEN INC 8-K Report, Financial Results (May 2, 2024)

Summary

Key Highlights

Frequently Asked Questions